Trial Profile

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Izalontamab brengitecan (Primary)
Indications Head and neck cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors Sichuan Baili Pharmaceutical

Most Recent Events

03 Aug 2025 Planned number of patients changed from 96 to 570.
03 Aug 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Dec 2025.
23 May 2025 According to a SystImmune media release, company will be presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting taking place May 30 - June 3 in Chicago.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com